NVIDIA Corporation (NVDA) — closed signal from January 12, 2026
Partial Published before the outcome was known, scored automatically when the window closed on April 12, 2026 — +2.2% at the close.
Predicted vs. what happened
What happened
Reached 39% of the predicted growth at its peak, without hitting the target.
The thesis — published January 12, 2026
NVIDIA announced product updates and a big $1B AI lab with a drug company. Those moves expand who wants its chips beyond the biggest cloud providers, which could bring new customers and attention. Expect price jumps and drops over the next 0-3 months; consider buying near the stated zone if the price stays there.
Primary drivers
- New BioNeMo and Clara updates help spread AI use in life sciences
- $1B lab with Lilly signals more enterprise customers for AI tools
- NVIDIA leads AI hardware so it often benefits when investors take more risk
- Buying after a pullback can attract others if the price holds the support zone
How it played out
NVDA: thesis rose but missed the target
Lyra published NVDA at $184.60 on 2026-01-12, with 18% expected growth over a short-term window. The thesis pointed to BioNeMo and Clara updates, a $1B lab with Lilly, broader enterprise demand for artificial intelligence tools, NVIDIA's hardware lead, and a possible buyer response if the price held the $178 to $186 zone.
Inside the window, NVDA rose but never reached $217.83. Its peak was $197.63 on 2026-02-25, a 7.1% gain. By 2026-04-12, it ended at $188.63. The published direction was partly right, but the target was missed. The thesis partially played out.
What happened during the window
On 2026-03-16, Nvidia unveiled DLSS 5 at GTC 2026, according to Tom's Hardware. The report said it was planned for fall 2026.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.